Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Jul 2024: Trial registered, NCT06529731
  2. 23 Sep 2024: Trial started, NCT06529731

The trials

NCT06529731: Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

State
Under way
Phase
Phase 2
People
57 planned
Started
23 Sep 2024
Primary completion
31 Oct 2029
Arms
Cohort 1: IFN-γ + DLI (HLA-matched donor alloSCT recipient cohort), Cohort 2: IFN-γ + DLI (Haploidentical donor alloSCT recipient cohort)
Results
None posted
  1. 31 Jul 2024: Trial registered
  2. 23 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.